Premium
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Author(s) -
SimónTalero M.,
Buti M.,
Esteban R.
Publication year - 2012
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.2011.01521.x
Subject(s) - ribavirin , medicine , oseltamivir , drug , haemolysis , adverse effect , antiviral drug , chronic hepatitis , virology , hepatitis c , hepatitis , bone marrow suppression , hepatitis c virus , pharmacology , immunology , virus , chemotherapy , covid-19 , disease , infectious disease (medical specialty)
Summary. Treatment for hepatitis C virus is often complicated by anaemia from ribavirin‐related haemolysis and bone marrow suppression because of peginterferon alfa. An extensive literature search revealed no reports of drug interactions between ribavirin and oseltamivir. We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa/ribavirin when oseltamivir was added to treat influenza. The adverse events related to ribavirin and drug–drug interactions during therapy for hepatitis C are discussed.